Quercetin improves the effects of sorafenib on growth and migration of thyroid cancer cells
- 24 Downloads
In this study we tested the ability of co-administration of the nutraceutical quercetin in maintaining the anticancer effects of lower dosage of sorafenib against thyroid cancer cells in vitro. K1 and BCPAP cells treated with sorafenib 0.1 µM and quercetin 25 μM for 24 h showed a decrease in the cell proliferation rate (~70% vs untreated cells vs. ~30% reduction of sorafenib alone). Similar results were obtained in both cell lines regarding cell adhesion and migration properties, with stronger inhibition obtained when the two compounds were used in combination (~70% or ~50% vs untreated cells respectively). Finally, a significant increase of E-cadherin and decrease of N-cadherinexpression, indicating a reduced epithelial-mesenchymal transition, were determined by the association of the two compounds. In conclusion, maintenance of effective anticancer activity of lower doses of sorafenib against thyroid cancer cells may be obtained by the co-administration of quercetin. Further...
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
This article does not contain any studies with human participants or animals performed by any of the authors.
- 3.W. Yimaer, A. Abudouyimu, Y. Tian, S. Magaoweiya, D. Bagedati, H. Wen, Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in the treatment of advanced thyroid cancer: a meta-analysis of randomized controlled trials. Onco Targets Ther. 9, 1167–1173 (2016)PubMedPubMedCentralGoogle Scholar
- 4.L.A. Dunn, E.J. Sherman, S.S. Baxi, V. Tchekmedyian, R.K. Grewal, S.M. Larson, K.S. Pentlow, S. Haque, R.M. Tuttle, M.M. Sabra, S. Fish, L. Boucai, J. Walters, R.A. Ghossein, V.E. Seshan, A. Ni, D. Li, J.A. Knauf, D.G. Pfister, J.A. Fagin, A.L. Ho, Vemurafenib redifferentiation of BRAF mutant, RAI-refractory thyroid cancers. J. Clin. Endocrinol. Metab. 104(5), 1417–1428 (2019)CrossRefGoogle Scholar
- 8.E. Mutlu Altunda, T. Kasaci, A. Yilmaz, B. Karademir, S. Koçtürk, Y. Taga, A.S. Yalçin, Quercetin-induced cell death in human papillary thyroid cancer (B-CPAP) cells. J. Thyroid Res. 2016, 9843675 (2016)Google Scholar
- 9.N. Miceli, A. Filocamo, S. Ragusa, F. Cacciola, P. Dugo, L. Mondello, M. Celano, V. Maggisano, M.F. Taviano, Chemical characterization and biological activities of phenolic‐rich fraction from cauline leaves of Isatis tinctoria L. (Brassicaceae) growing in Sicily, Italy. Chem. Biodivers. 14(8), e1700073 (2017)Google Scholar
- 10.V. Maggisano, M. Celano, S.M. Lepore, M. Sponziello, F. Rosignolo, V. Pecce, A. Verrienti, F. Baldan, C. Mio, L. Allegri, M. Maranghi, R. Falcone, G. Damante, D. Russo, S. Bulotta, Human telomerase reverse transcriptase in papillary thyroid cancer: gene expression, effects of silencing and regulation by BET inhibitors in thyroid cancer cells. Endocrine 63(3), 545–553 (2019)CrossRefGoogle Scholar
- 11.M. D’Agostino, P. Voce, M. Celano, M. Sponziello, S. Moretti, V. Maggisano, A. Verrienti, C. Durante, S. Filetti, E. Puxeddu, D. Russo, Sunitinib exerts only limited effects on the proliferation and differentiation of anaplastic thyroid cancer cells. Thyroid 22(2), 138–144 (2012)CrossRefGoogle Scholar
- 12.V. Maggisano, M. Celano, S. Lepore, G.E. Lombardo, M. Sponziello, F. Rosignolo, A. Verrienti, F. Baldan, E. Puxeddu, C. Durante, S. Filetti, G. Damante, D. Russo, S. Bulotta, Silencing of hTERT blocks growth and migration of anaplastic thyroid cancer cells. Mol. Cell. Endocrinol. 448, 34–40 (2017)CrossRefGoogle Scholar
- 14.M. Sponziello, F. Rosignolo, M. Celano, V. Maggisano, V. Pecce, R.F. De Rose, G.E. Lombardo, C. Durante, S. Filetti, G. Damante, D. Russo, S. Bulotta, Fibronectin-1 expression is increased in aggressive thyroid cancer and favors the migration and invasion of cancer cells. Mol. Cell. Endocrinol. 431, 123–132 (2016)CrossRefGoogle Scholar
- 20.G.E. Lombardo, V. Maggisano, M. Celano, D. Cosco, C. Mignogna, F. Baldan, S.M. Lepore, L. Allegri, S. Moretti, C. Durante, G. Damante, M. Fresta, D. Russo, S. Bulotta, E. Puxeddu, Anti-hTERT siRNA-loaded nanoparticles block the growth of anaplastic thyroid cancer xenograft. Mol. Cancer Ther. 17(6), 1187–1195 (2018)CrossRefGoogle Scholar